Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compounds, compositions, and methods

a technology of compositions and compounds, applied in the field of compositions and methods, can solve the problems of limiting the usefulness of compounds, inducing cancer cell death, and inhibiting cancer cell division

Inactive Publication Date: 2006-01-26
CYTOKINETICS INC
View PDF56 Cites 106 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0028] In a further aspect, the invention provides methods of screening for modulators of KSP kinesin activity. The methods comprise combining a comp

Problems solved by technology

It is presumed that disruption of the mitotic spindle by these drugs results in inhibition of cancer cell division, and induction of cancer cell death.
Because these agents do not specifically target mitotic spindles, they have side effects that limit their usefulness.
Experimental perturbation of mitotic kinesin function causes malformation or dysfunction of the mitotic spindle, frequently resulting in cell cycle arrest and cell death.
Microinjection of antibodies directed against KSP into human cells prevents spindle pole separation during prometaphase, giving rise to monopolar spindles and causing mitotic arrest and induction of programmed cell death.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compounds, compositions, and methods
  • Compounds, compositions, and methods
  • Compounds, compositions, and methods

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0344] Synthesis of Compounds

[0345] A solution of 4-chloro-2-iodobenzoic acid 1 (25 g, 88.7 mmol), SOCl2 (100 mL), and DMF (few drops) was warmed gently with a heat gun until the mixture became homogeneous (15 mins). The solution was maintained at 23° C. for an additional 30 mins, then the solution was concentrated. MeOH (200 mL) was added to the crude residue and the solution was maintained at 23° C. for 30 mins. The solution was concentrated and the crude residue was then dissolved in 10:1 hexanes:EtOAc and passed through a plug of silica gel. The eluent was concentrated to provide 26.2 g (100%) of ester 2 as a colorless oil, which solidified upon standing under high vacuum (0.1 Torr).

[0346] A mixture of ester 2 (2.35 g, 7.94 mmol), acetylene 31 (1.72 g, 8.7 mml), Pd(PPh3)Cl2 (140 mg, 0.20 mmol), Cul (19 mg, 0.1 mmol), and TEA (35 mL) was maintained at 50° C. for 1 h. The reaction mixture was diluted with EtOAc (200 mL), washed with water (100 mL), then brine (100 mL). The orga...

example 2

[0353] Synthesis of Compounds

[0354] Isoquinolone 8 (515 mg, 1.47 mmol), aldehyde 12 (255 mg, 1.47 mmol), NaCN(OAc)3BH (420 mg, 1.98 mmol), and CH2Cl2 (4.1 mL) was maintained at 23° C. for 2 h. An additional portion of 12 (225 mg, 1.30 mmol) in CH2Cl2 (0.6 mL) was then added. After an additional 3 h, the reaction mixture was diluted with EtOAc (20 mL) and washed with 1 N NaOH (5 mL) and brine (5 mL). The organic layer was dried (MgSO4), filtered, and concentrated. The resulting residue was purified by flash column chromatography (3:1 hexanes:EtOAc; 1:1 hexanes:EtOAc) to yield 630 mg (86%) of 13.

[0355] To a solution of isoquinolone 13 (85 mg, 0.17 mmol), diisoproylethylamine (DIEA, 0.12 mL, 0.68 mmol), and CH2Cl2 (0.6 mL) at 23° C. was added p-toluoyl chloride (45 μL, 34 mmol). After 4 h, the reaction mixture was diluted with EtOAc (20 mL) and washed with saturated aqueous NaHCO3 (5 mL) and brine (5 mL). The organic layer was dried (MgSO4), filtered, and concentrated. The resulting...

example 3

[0357] Using the methods of the invention as exemplified in Examples 1 and 2 above, the following compounds were prepared:

LRMSStructure(MH) m / z516.2470.2512.2575.8528.0464.0530.0516.2566.2512.2565.8558.2

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Configurationaaaaaaaaaa
Login to View More

Abstract

Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed.

Description

CROSS-REFERENCE TO RELATED PATENT APPLICATIONS [0001] This application claims the benefit of U.S. Provisional Patent Application No. 60 / 389,265, filed Jun. 14, 2002 and of U.S. Provisional Patent Application No. 60 / 389,779, filed Jun. 18, 2002; each of which is incorporated herein by reference for all purposes.FIELD OF THE INVENTION [0002] This invention relates to compounds which are inhibitors of the mitotic kinesin KSP and are useful in the treatment of cellular proliferative diseases, for example cancer, hyperplasias, restenosis, cardiac hypertrophy, immune disorders, fungal disorders, and inflammation. BACKGROUND OF THE INVENTION [0003] Among the therapeutic agents used to treat cancer are the taxanes and vinca alkaloids, which act on microtubules. Microtubules are the primary structural element of the mitotic spindle. The mitotic spindle is responsible for distribution of replicate copies of the genome to each of the two daughter cells that result from cell division. It is pre...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D217/22A61K31/47A61K31/472A61K31/4725A61K45/00A61P9/00A61P29/00A61P35/00A61P37/00A61P43/00C07D217/24C07D401/06
CPCC07D401/06C07D217/24A61P29/00A61P35/00A61P37/00A61P43/00A61P9/00
Inventor MCDONALD, ANDREWLU, PU-PINGBERGNES, GUSTAVEMORGANS, DAVID J. JR.DHANAK, DASHYANTKNIGHT, STEVEN DAVID
Owner CYTOKINETICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com